EU-US MRA: New Commitment
On the Road to 30,000 Members
Let us become the World's Leading GMP/GDP Compliance Community in 2026
The European Commission (EC), the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have signed a new confidentiality commitment allowing to share non-public and commercially confidential information relating to medicine inspections between inspectorates.
This commitment is an important part in the ongoing implementation of the mutual recognition of inspections of medicine manufacturers (Mutual Recognition Agreement; MRA), which should come into force on 1st November 2017.
Confidentiality arrangements have already been in place since 2003, supporting the exchange of confidential information as part of regulatory and scientific processes. However, complete exchange of information including trade secret information has not been possible yet. Now it will be possible to share full inspection reports.
Source: EMA press release Strengthening EU-US cooperation in medicine inspections
Related GMP News
17.12.2025EU Reaches Landmark on Reform of Pharmaceutical Legislation
12.11.2025GMP for Veterinary Products: Implementing Regulations published
22.10.2025Content Review of the Audit Trail Review
15.10.2025Executing the Audit Trail Review
08.10.2025Risk-based Determination of the Scope and Frequency of Audit Trail Reviews